Close Menu

marketing agreement

Ion Torrent will offer software from Partek and DNAStar directly through its online store, and it has inked a service and support deal with BioTeam for the Ion Torrent Server and Torrent Suite Software.

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.

The instruments were acquired just three months ago by Cellectis from Cyto Pulse Sciences.

LightArray will offer a variety of Aushon's multiplex biomarker products and services in China.

Rosetta has regained US commercial rights from Prometheus for its miRview mets, miRview squamous, and miRview meso tests.

Cepheid will receive $5 million in an upfront payment and $3 million in milestone payments over the next 12 months as part of the deal, while Novartis would have exclusive global distribution rights to the test upon its commercialization in the US.

Abbott will be the exclusive distributor of the KIF6 test in the European Union and other areas that recognize the CE mark.

Waters expects the deal to result in its products being offered to a broader use base.

ARUP will begin offering the test, which measures 25 common SNPs associated with prostate cancer risk, in the fall.

Thermo Fisher's sample handling and mass spectrometers will be integrated with IBI's proprietary immunoenrichment technology, and the two firms will develop assays and workflows for the detecting and quantifying low abundance proteins.


CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.